The Success Genome
August Troendle
← browse
Founder · Capital · Biotechnology · Business Services · $1–10B

August Troendle

Founder, chairman and CEO of Medpace, a Cincinnati contract research organization that runs clinical trials for drug and device makers · b. 1956 · Not established in the sources consulted; based in Cincinnati, Ohio since founding Medpace

unknownunknownunknown (childhood not documented)
Medpace
Cost of failure 4 / 10
soft landingnothing to catch a fall
Headwinds 0 / 10
clear runagainst the current

Two calls made by hand, not formulas. how we score →

Summary

A physician who worked a year at the FDA and five at Sandoz, then started a clinical trial services firm in Cincinnati in 1992.

Private equity bought in twice, in 2011 and 2014, and he kept a large stake through the 2016 IPO. He owns about 19.6 percent of a public company, and Forbes puts him at $4.6 billion. How he paid for the start is not on the record.

Coded record
industryBiotechnology · Business Services
talenthigh
connectionssome
outcome size$1–10B · band 5
path typeFounder · Capital
childhood householdtwo-parent
immigrant generationnone
educationgraduate degree
credential fundingnone
startup capitalwage-savings
took outside investmentyes
kept ownershipyes
public scrutinyregulatory
ⓘ Hover any row for its definition.
Subject cooperation: public-only · last reviewed 2026-10-18

Where they worked

Medpace Founder, Chief Executive Officer and Chairman of the Board · 1992–now founder still there

How it happened

iWhat the record doesn't say

Almost nothing is published about Troendle's childhood, parents or early finances. There's no Wikipedia article on him. Medpace's proxy statements give his age (69 in March 2026) and Forbes gives 70 in October 2026, which points to a 1956 birth year. Where he grew up, what his family did and how he paid for school aren't established in the sources consulted, so those fields stay empty here rather than guessed.

iiMedicine, an MBA and the FDA

The 2026 proxy says he holds a medical degree from the University of Maryland School of Medicine and an MBA from Boston University. From 1986 to 1987 he was a Medical Review Officer in the FDA's Division of Metabolic and Endocrine Drug Products. Forbes says he reviewed cholesterol-lowering drugs there. That is a regulator's seat on exactly the kind of trials he'd later run for other companies.

iiiSandoz

From 1987 to 1992 he was a manager at Sandoz, now part of Novartis, responsible for the clinical development of lipid-altering agents. Forbes describes the role as a director. The proxy's wording is manager, and that is what this record uses. He'd now seen the same process from the regulator's side and from the sponsor's side.

ivMedpace
Turning point

Troendle founded Medpace in July 1992 in Cincinnati and has been CEO and chairman since. The 2016 IPO prospectus calls it a Phase II to IV focused research organization that has grown almost exclusively organically. How much money he put in, whether anyone else backed the first years, and whether he started with co-founders aren't stated in the filings or press consulted. A Wikipedia mirror says the original name was Medical Research Services; that rests on one source.

vPrivate equity and the IPO

According to Wikipedia, CCMP Capital bought 80 percent of the firm in 2011. The IPO prospectus describes the next step: in 2014 Cinven bought the company for $921.3 million, with Medpace employees rolling shares into a vehicle, Medpace Investors, LLC, that held about 25 percent afterward. Medpace listed on Nasdaq in August 2016. At the IPO Troendle was listed as beneficial owner of 24.1 percent, much of it through that vehicle, which he controls.

viWhere it stands

The 2026 proxy shows him owning 19.6 percent of Medpace. His 2025 reported compensation was $11.4 million, almost all of it a stock option grant, and he exercised options in 2025 for $91.6 million in realized value. Forbes lists his net worth at $4.6 billion as of October 18, 2026, ranked 934th, and calls him self-made.

Can you replicate their success?

Partly

The first half of this route is a credentialed one: medical school, a regulator's desk and a sponsor-side job at a large drugmaker, all of which produce a steady income. The second half is harder to read, because the record doesn't say how the 1992 start was funded. Contract research has since consolidated around large players, and a newcomer would now be competing against firms with global trial networks. Still, the knowledge that made Medpace possible, seeing clinical trials from both the regulator's and the sponsor's side, can be acquired in jobs anyone with the credential can apply for.

Required conditions
1 A medical degree, and an MBA or equivalent business training
2 Several years inside a regulator and a large drug company, learning how trials are judged and run
3 Enough savings, backers or income to carry a services firm through its first years (the actual start-up funding is not documented)
4 Drug and device sponsors willing to give an unproven firm its first trials
5 Later, a private equity partner willing to buy in while the founder keeps a large stake

The coded evidence

Thirteen groups, every claim sourced
Feeds cost of failure
Parent Occupations
Low

not established

Not established. Neither Forbes nor the SEC filings say.

↗ forbes.com
Parental Self Employment
Low

not established

Not established.

↗ forbes.com

Structural context

founder lens · venture capital

The cost-of-failure score comes from this person's own money and circumstances. But who they were in America carried its own weight, the same way their household or income did, and it shaped how hard the path was just as much. That part isn't in the cost-of-failure number. It's here instead.

tailwindman

Men founded the companies that took nearly all the venture funding and almost every top outcome, a tailwind that never shows up in one person's own circumstances.

↗ techcrunch.com

Among the people recorded here — men: 225. Representation here is who reached these outcomes, not equal odds of reaching them.

Controlled comparisons

Each holds one thing constant and varies another, so the difference is the point. A list of similar names wouldn't tell you anything.